Alan Parker

Alan Parker is Head of Solid Cancers and Professor of Translational Virology at Cardiff University School of Medicine, NIHR Senior Investigator, and CSO at Accession Therapeutics. He leads the Viral Immunotherapies and Advanced Therapeutics (VITAL) - a large and vibrant lab at Cardiff University. His team study the adenovirus, and the host: cell interactions that underpin cellular infection and tropism. Using this, his team develop refined, tumour selective and clinically tractable virotherapies for translational applications in the oncology setting. The first of those agents, ATTR-01, entered first-in-human clinical evaluation in αvβ6 integrin positive disease in 2025. Prior to relocating to Cardiff in 2013, Alan spent 8 years as a Postdoc and the Royal Society of Edinburgh Personal Research Fellow at the University of Glasgow (2005-2013), and two years at King’s College London (2003-2005). Alan is a long-standing board member (2014-2024 and 2025-) and Treasurer (2020-2024) of the Bri